{"id":"placebo-0-9-w-v-sodium-chloride-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (if administered parenterally)"},{"rate":null,"effect":"Hypernatremia (with excessive or prolonged use)"},{"rate":null,"effect":"Fluid overload (with large volume administration)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Normal saline (0.9% w/v NaCl) is a sterile solution with osmolarity matching human blood plasma, making it suitable for intravenous, intramuscular, or topical administration without causing cellular damage. In Phase 3 trials, it is typically used as a placebo control to establish the efficacy of an investigational therapeutic agent by comparison against an inert standard.","oneSentence":"0.9% sodium chloride solution is an isotonic saline that serves as a physiologically inert vehicle for drug delivery or as a control comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:20.335Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control in Phase 3 clinical trials"}]},"trialDetails":[{"nctId":"NCT01915212","phase":"PHASE1","title":"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09-26","conditions":"Healthy Volunteers","enrollment":69},{"nctId":"NCT05002998","phase":"PHASE4","title":"TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-09-16","conditions":"Thyroid Eye Disease","enrollment":313},{"nctId":"NCT00636480","phase":"PHASE3","title":"Preoperative Skin Preparation Evaluation","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2007-10","conditions":"Topical Antisepsis","enrollment":60},{"nctId":"NCT07220915","phase":"PHASE3","title":"Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections","status":"NOT_YET_RECRUITING","sponsor":"Octapharma","startDate":"2025-12","conditions":"Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions","enrollment":360},{"nctId":"NCT07050511","phase":"PHASE1","title":"Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Generate Biomedicines","startDate":"2023-07-18","conditions":"SARS CoV-2","enrollment":51},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT03173625","phase":"PHASE1","title":"A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2016-11-29","conditions":"Healthy Subjects","enrollment":72},{"nctId":"NCT04870333","phase":"PHASE2, PHASE3","title":"PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-02-19","conditions":"Covid19","enrollment":2240},{"nctId":"NCT04661839","phase":"PHASE1","title":"A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2020-12-24","conditions":"COVID-19","enrollment":28},{"nctId":"NCT04016246","phase":"PHASE3","title":"Respiratory Effect of the LISA Method with Sedation by Propofol Versus Absence of Sedation.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2019-10-07","conditions":"Respiratory Distress Syndrome in Premature Infant","enrollment":233},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT05567783","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A","status":"TERMINATED","sponsor":"Vir Biotechnology, Inc.","startDate":"2022-10-30","conditions":"Influenza A","enrollment":2977},{"nctId":"NCT03298867","phase":"PHASE3","title":"Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-10-04","conditions":"Thyroid Eye Disease, Graves' Orbitopathy","enrollment":83},{"nctId":"NCT04478994","phase":"PHASE1","title":"A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-11-17","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":3},{"nctId":"NCT03341676","phase":"PHASE1","title":"Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)","status":"COMPLETED","sponsor":"University Hospitals Coventry and Warwickshire NHS Trust","startDate":"2019-01-14","conditions":"High Altitude Cerebral Edema","enrollment":10},{"nctId":"NCT04988152","phase":"PHASE1","title":"A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2021-07-06","conditions":"Covid19","enrollment":48},{"nctId":"NCT04711005","phase":"PHASE1","title":"Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2021-01-11","conditions":"Major Depressive Disorder","enrollment":74},{"nctId":"NCT03074591","phase":"PHASE4","title":"Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2017-08-01","conditions":"Iron-deficiency, Heart Failure","enrollment":40},{"nctId":"NCT03980483","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-05-16","conditions":"Arthritis, Rheumatoid","enrollment":1537},{"nctId":"NCT04185415","phase":"PHASE1","title":"A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-12-03","conditions":"Progressive Supranuclear Palsy","enrollment":25},{"nctId":"NCT04120415","phase":"PHASE2","title":"A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-06-21","conditions":"HIV-1-infection","enrollment":2},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT05561010","phase":"NA","title":"Understanding Pain Mechanisms in Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-10","conditions":"Osteoarthritis, Knee, Chronic Pain","enrollment":50},{"nctId":"NCT04690335","phase":"PHASE2","title":"Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine","status":"COMPLETED","sponsor":"Meissa Vaccines, Inc.","startDate":"2020-12-29","conditions":"RSV Infection","enrollment":60},{"nctId":"NCT05477498","phase":"PHASE4","title":"Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction","status":"WITHDRAWN","sponsor":"Cantonal Hosptal, Baselland","startDate":"2021-12-01","conditions":"Heart Failure With Normal Ejection Fraction, Iron-deficiency","enrollment":""},{"nctId":"NCT05467319","phase":"PHASE3","title":"Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS","status":"UNKNOWN","sponsor":"Alberta Health Services, Calgary","startDate":"2022-09-30","conditions":"Gynecologic Cancer, Anemia, Iron Deficiency, Surgery","enrollment":82},{"nctId":"NCT04862715","phase":"PHASE4","title":"The Iron and Muscle Study","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2019-04-26","conditions":"CKD Stage 3, CKD Stage 4, Iron-deficiency","enrollment":75},{"nctId":"NCT02667639","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2016-01","conditions":"Healthy","enrollment":35},{"nctId":"NCT03984812","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2019-06-17","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT03287310","phase":"PHASE1","title":"First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-17","conditions":"Asthma","enrollment":50},{"nctId":"NCT02504671","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-23","conditions":"Arthritis, Rheumatoid","enrollment":222},{"nctId":"NCT02799472","phase":"PHASE2","title":"Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-15","conditions":"Arthritis, Rheumatoid","enrollment":39},{"nctId":"NCT03965533","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-06-10","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT03417661","phase":"PHASE3","title":"An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes","status":"COMPLETED","sponsor":"Gama Healthcare Ltd.","startDate":"2018-06-29","conditions":"Antimicrobial Effect","enrollment":93},{"nctId":"NCT03245619","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-08-22","conditions":"Pancreatitis, Acute Necrotizing","enrollment":18},{"nctId":"NCT04176653","phase":"PHASE1","title":"Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124","status":"WITHDRAWN","sponsor":"Silence Therapeutics plc","startDate":"2019-08-20","conditions":"Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT02425241","phase":"PHASE1, PHASE2","title":"Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"HIV","enrollment":41},{"nctId":"NCT02972450","phase":"PHASE1, PHASE2","title":"An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection","status":"TERMINATED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2019-02-20","conditions":"HIV-1-infection","enrollment":1},{"nctId":"NCT03398681","phase":"PHASE4","title":"Changes in Myocardial Iron After Iron Administration","status":"COMPLETED","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2017-05-01","conditions":"Heart Failure, Iron-deficiency","enrollment":53},{"nctId":"NCT02000817","phase":"PHASE1, PHASE2","title":"Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-12","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT03682471","phase":"","title":"Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-02-14","conditions":"Subcutaneous Fat","enrollment":201},{"nctId":"NCT02671188","phase":"PHASE1","title":"A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-06-01","conditions":"Autoimmune Diseases","enrollment":""},{"nctId":"NCT01899755","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-10","conditions":"Psoriasis","enrollment":45},{"nctId":"NCT02953808","phase":"PHASE1","title":"Phase 1 Study of GSK2315698 in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11","conditions":"Amyloidosis","enrollment":18},{"nctId":"NCT02456558","phase":"PHASE1","title":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2015-06","conditions":"Asymptomatic HIV Infection","enrollment":30},{"nctId":"NCT01388504","phase":"PHASE2, PHASE3","title":"Nitrites in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2011-07","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":200},{"nctId":"NCT00357279","phase":"PHASE3","title":"Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Cystic Fibrosis","enrollment":352},{"nctId":"NCT00625612","phase":"PHASE3","title":"Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Cystic Fibrosis","enrollment":466},{"nctId":"NCT01181622","phase":"PHASE2","title":"A Safety and Tolerability Study of Denufosol in 2-4 Year Olds","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-08","conditions":"Cystic Fibrosis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo - 0.9% w/v sodium chloride solution","genericName":"Placebo - 0.9% w/v sodium chloride solution","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"0.9% sodium chloride solution is an isotonic saline that serves as a physiologically inert vehicle for drug delivery or as a control comparator in clinical trials. Used for Placebo control in Phase 3 clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}